Press Release – Düsseldorf and Heppenheim: Plusultra pharma GmbH and InfectoPharm Arzneimittel und Consilium GmbH announced today the signing of a binding Term Sheet for the exclusive commercialisation of the product Hyftor® 2mg/g Gel in France and Italy. InfectoPharm will promote and distribute the product in these two countries, thereby expanding the market for Hyftor® 2mg/g Gel.
Hyftor® is a centrally authorised orphan drug and contains the active pharmaceutical ingredient sirolimus. It is a topical mTOR inhibitor immunosuppressant drug indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and paediatric patients aged 6 years and older. TSC is a genetic disorder that causes tissue growth resulting in benign tumors affecting various organs and regions of the body, most commonly the brain, eyes, heart, kidneys, skin and lungs.
„We are excited to partner with Plusultra pharma and to add Hyftor® to our product portfolio“, said Philipp Zöller, Managing Director of InfectoPharm. „Hyftor® is the first and only authorised drug product in the European Union for the treatment of facial angiofibroma in TSC patients and has the potential to be a game-changer in the treatment of this condition meeting an unmet medical need in these patients. At the same time Hyftor® will be the first orphan drug in InfectoPharm’s portfolio and InfectoPharm is very proud to offer this product as new therapeutic option to prescribers and patients in France and Italy. Our organizations in France and Italy are well-equipped to handle the commercialization of Hyftor®,“ added Philipp Zöller. „Both have marketing and field force teams with extensive scientific expertise, as well as Medical Science Liaison Managers who maintain strong relationships with Key Opinion Leaders. Many of our employees have long-standing experience in the pharmaceutical industry, particularly in dealing with complex therapeutic areas. This uniquely positions us to effectively introduce and support Hyftor® in these markets.”
„Hyftor® has the potential to be a game-changer in the treatment of facial angiofibroma in TSC patients.“
„We are pleased to enter into this agreement with InfectoPharm,“ said Takahiro Yamasaki, Managing Director of Plusultra pharma. „We believe that this product, as the first approved treatment option for facial angiofibroma associated with TSC, will contribute to patients‘ quality of life. This collaboration will allow more patients to have access to the product in Europe.”
About InfectoPharm
InfectoPharm Arzneimittel und Consilium GmbH, founded in 1988 and located in Heppenheim, Germany, is a leading pharmaceutical company in pediatrics and also one of the leading German companies in dermatology. For over 35 years, this medium-sized, family-owned company has distinguished itself as a groundbreaking pioneer in various fields of therapeutic indications. The InfectoPharm group is increasingly expanding its international business with own subsidiaries in Austria, France, Italy, and the UK operating with highly qualified scientific sales force teams in those countries to promote a selected part of the headquarters’ portfolio. The InfectoPharm group achieved revenues of about Euro 300 million in 2024 with an average growth rate of about 10 percent.
InfectoPharm Arzneimittel und Consilium GmbH
Von-Humboldt-Str. 1
64646 Heppenheim
Germany
About Plusultra pharma GmbH
Plusultra pharma GmbH was founded in 2020 as a subsidiary of the Japanese company Nobelpharma Co. Ltd. in Europe, based in Düsseldorf, Germany. Like its parent company, Plusultra pharma GmbH focuses on the treatment of rare diseases. Following approval by the EMA in May 2023 and by the MHRA in UK in September 2023, the first product Hyftor® 2mg/g Gel (sirolimus 0.2%) for the treatment of facial angiofibroma associated with TSC was launched on the German and the UK market in November 2023.
Plusultra pharma GmbH
Fritz-Vomfelde-Str. 36
40547 Düsseldorf
Germany
Weblinks
InfectoPharm Arzneimittel und Consilium GmbH (English)
Plusultra pharma GmbH
Company contact
InfectoPharm Arzneimittel und Consilium GmbH
Dr. Markus Rudolph
COO/Managing Director InfectoPharm
Email: Markus.Rudolph@Infectopharm.com